Shield Therapeutics plc (AIM:STX)
London · Delayed Price · Currency is GBP · Price in GBX 4.910
+0.010 (0.20%)
Aug 21, 2026, 3:59 PM GMT
Shield Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 11.62 | 6.52 | 13.95 | 3.4 | 16.41 |
Cash & Short-Term Investments | 11.62 | 6.52 | 13.95 | 3.4 | 16.41 |
Cash Growth | 78.13% | -53.23% | 309.99% | -79.27% | 308.75% |
Accounts Receivable | 19.77 | 12.28 | 9.99 | 3.39 | 1.1 |
Other Receivables | 2.36 | 10.54 | 1.23 | 1.13 | 1.3 |
Receivables | 22.13 | 22.81 | 11.21 | 4.52 | 2.4 |
Inventory | 9.21 | 5.66 | 3.2 | 1.76 | 2.21 |
Prepaid Expenses | 2.25 | 2.44 | 2.9 | 2.5 | 2.35 |
Restricted Cash | - | 0.5 | - | - | - |
Total Current Assets | 45.22 | 37.94 | 31.26 | 12.17 | 23.37 |
Property, Plant & Equipment | 0.11 | 0.37 | 0.67 | 0.24 | 0.41 |
Other Intangible Assets | 0.99 | 1.05 | 1.18 | 1.23 | 23.46 |
Long-Term Deferred Charges | 17.9 | 17.12 | 15.68 | 12.98 | 12.9 |
Other Long-Term Assets | 1 | 1 | - | - | - |
Total Assets | 65.22 | 57.48 | 48.8 | 26.62 | 60.14 |
Liabilities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 11.48 | 6.52 | 4.05 | 1.74 | 1.78 |
Accrued Expenses | 25.94 | 16.67 | 8.67 | 9.71 | 2.9 |
Current Portion of Leases | - | 0.2 | 0.21 | 0.11 | 0.21 |
Current Income Taxes Payable | 0.07 | 0.05 | 0.1 | 0.27 | 0.07 |
Other Current Liabilities | 12.66 | 9.19 | 0.7 | 1.01 | 0.08 |
Total Current Liabilities | 50.16 | 32.62 | 13.74 | 12.83 | 5.04 |
Long-Term Debt | 30.14 | 26.17 | 19.84 | 6.68 | - |
Long-Term Leases | - | - | 0.2 | - | - |
Other Long-Term Liabilities | - | - | - | 0.56 | - |
Total Liabilities | 80.29 | 58.8 | 33.77 | 20.07 | 5.04 |
Shareholders' Equity
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 20.44 | 19.91 | 15.01 | 5.37 | 4.38 |
Additional Paid-In Capital | 204.61 | 203.19 | 198.76 | 169.48 | 155.15 |
Retained Earnings | -276.71 | -259.85 | -233.53 | -201.11 | -144.8 |
Comprehensive Income & Other | 36.59 | 35.43 | 34.79 | 32.8 | 40.36 |
Shareholders' Equity | -15.08 | -1.32 | 15.03 | 6.54 | 55.1 |
Total Liabilities & Equity | 65.22 | 57.48 | 48.8 | 26.62 | 60.14 |
Additional Metrics
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 30.14 | 26.37 | 20.25 | 6.79 | 0.21 |
Net Cash (Debt) | -18.51 | -19.85 | -6.3 | -3.39 | 16.2 |
Net Cash Growth | - | - | - | - | 307.37% |
Net Cash Per Share | -0.02 | -0.03 | -0.01 | -0.01 | 0.08 |
Filing Date Shares Outstanding | 1,068 | 1,042 | 782.06 | 259.39 | 215.89 |
Total Common Shares Outstanding | 1,068 | 1,042 | 782.06 | 259.39 | 215.89 |
Working Capital | -4.94 | 5.32 | 17.53 | -0.66 | 18.33 |
Book Value Per Share | -0.01 | -0.00 | 0.02 | 0.03 | 0.26 |
Tangible Book Value | -16.07 | -2.36 | 13.85 | 5.31 | 31.64 |
Tangible Book Value Per Share | -0.02 | -0.00 | 0.02 | 0.02 | 0.15 |
Machinery | 0.38 | 0.51 | 0.48 | 0.24 | 0.27 |